Abstract: Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we examined longitudinal antibody responses and viral neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern (VOCs: Alpha, Beta, Gamma, and Delta) and a local variant of interest (VOI: Lambda) in volunteers receiving the Sputnik V vaccine in Argentina. A collection of 472 serum samples obtained between January and September 2021 was used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing capacity to the first-wave linages of SARS-CoV-2 and VOC are maintained within four months of vaccination. In addition, an improved antibody cross-neutralizing ability to circulating variants of concern (Beta, Gamma and Delta) was observed over time of vaccination. The viral variants that displayed higher escape to neutralizing antibodies with respect to the original virus (Beta and Gamma variants) were the ones showing the largest increase in susceptibility to neutralization over time after vaccination. Our observations indicate that serum neutralizing antibodies are maintained for at least four month and show a reduction of VOC escape over time of vaccination.
Introduction: Addressing Immunity Waning and Viral Variants
A major concern throughout the COVID-19 pandemic has been the "waning" of vaccine-induced immunity. Early studies often focused on the rapid decline of total IgG antibodies, leading to concerns that protection might disappear within months. Furthermore, the emergence of variants of concern (VOCs) like Alpha, Beta, Gamma, and Delta raised questions about whether vaccines designed against the original Wuhan strain would remain effective long-term.
While much research has focused on mRNA platforms, less was known about the long-term kinetics of the Sputnik V vaccine—a heterologous viral vector platform (rAd26 and rAd5). This study sought to determine if the immune response to Sputnik V evolves over time to better handle viral mutations through a process known as antibody affinity maturation.
Methodology
Researchers conducted a longitudinal study in Argentina, following 118 healthcare workers for four months post-vaccination. A total of 472 serum samples were collected at four intervals: baseline, 21 days, 42 days, and 120 days. The cohort included 88 individuals with no prior infection and 30 with prior COVID-19 (hybrid immunity).
The immune response was evaluated using three primary methods:
- ELISA Titration: Quantifying anti-spike IgG levels using the WHO International Antibody Standard.
- Pseudotyped Virus Neutralization: Using modified VSV expressing spike proteins of Wuhan, Alpha, Beta, Gamma, and Delta variants.
- Live Virus Neutralization: The "gold standard" test using actual SARS-CoV-2 isolates (B.1, Alpha, Gamma, and Lambda) in a BSL-3 laboratory.
Key Findings: Antibody Quality vs. Quantity
The most striking finding is the divergence between antibody levels and antibody potency. While the total amount of anti-spike IgG dropped significantly by day 120, the ability of those remaining antibodies to neutralize the virus stayed remarkably stable. In naïve individuals, IgG levels dropped from a geometric mean of 758 IU/ml at 42 days to 228 IU/ml at 120 days. However, the geometric mean neutralizing titer (GMT IC50) showed no significant reduction over the same period.
This suggests that B-cells continue to "train" in the months following vaccination, resulting in antibodies that bind more tightly to the virus (affinity maturation), effectively compensating for the lower overall concentration.
Enhanced Neutralization of Variants of Concern
Initially, variants like Beta and Gamma showed high "escape," meaning they were significantly harder for vaccine-induced antibodies to neutralize than the original Wuhan strain. However, the study found that the "escape gap" closed over time. The antibodies became progressively better at recognizing and neutralizing the very variants that were previously most resistant.
Specifically, at 42 days, the Beta variant showed a 19.2-fold reduction in neutralization compared to the original strain. By 120 days, this escape dropped to 9.7-fold. Similarly, the Gamma variant improved from a 13.8-fold reduction to a 4.2-fold reduction. The local variant of interest, Lambda, showed a modest 2.8 to 2.9-fold reduction, suggesting Sputnik V remains effective against regional threats in South America.
Conclusion and Future Outlook
These observations indicate that while total antibody quantity wanes, the quality of the immune response to Sputnik V improves over at least four months. This maturation leads to more durable protection and a broader ability to neutralize emerging variants.
Limitations of the study include its four-month timeframe and focus exclusively on humoral (antibody) immunity. Future research is needed to evaluate cellular immunity (T-cells) and define the exact thresholds of antibodies required to prevent infection versus severe disease over longer periods.
Summary updated